The goal of this study is a technology analysis of a revolution for the management of valvular heart diseases given by new technological system based on transcatheter artificial aortic valve, a delivery catheter and a loading system for the treatment of aortic stenosis (a narrowing of the aortic valve because of calcium build up that restricts blood flow to aorta, the body's main artery) in patients at intermediate and greater risk for surgical therapy. In particular, this study analyzes the technological trajectories of new technology of transcatheter aortic valve implantation (TAVI) in relation to the established technology of surgical aortic valve replacement (SAVR). To explore the emerging technology of TAVI for valvular heart diseases, a model is applied to show how new TAVI technology is substituting established technologies of SAVR to revolutionize the management of aortic stenosis in cardiology. Statistical analyses reveal the sharp increase of the scientific production of TAVI that has a coefficient of growth as function of time equal to 0.40 (p<.001) versus a coefficient for SAVR technology of 0.10 (p<.001). This finding suggests a technological forecasting that TAVI will be the dominant technology for the treatment of patients with valvular heart diseases. Overall, then, this study shows that new technology of transcatheter aortic valve implantation (TAVI) introduced in 2002 is growing in terms of scientific, inventive and innovative activity to revolutionize the management of aortic stenosis in cardiology worldwide.
A new technological system to revolutionize the management of valvular heart diseases: transcatheter aortic valve for the treatment of aortic stenosis
Coccia Mario
2019
Abstract
The goal of this study is a technology analysis of a revolution for the management of valvular heart diseases given by new technological system based on transcatheter artificial aortic valve, a delivery catheter and a loading system for the treatment of aortic stenosis (a narrowing of the aortic valve because of calcium build up that restricts blood flow to aorta, the body's main artery) in patients at intermediate and greater risk for surgical therapy. In particular, this study analyzes the technological trajectories of new technology of transcatheter aortic valve implantation (TAVI) in relation to the established technology of surgical aortic valve replacement (SAVR). To explore the emerging technology of TAVI for valvular heart diseases, a model is applied to show how new TAVI technology is substituting established technologies of SAVR to revolutionize the management of aortic stenosis in cardiology. Statistical analyses reveal the sharp increase of the scientific production of TAVI that has a coefficient of growth as function of time equal to 0.40 (p<.001) versus a coefficient for SAVR technology of 0.10 (p<.001). This finding suggests a technological forecasting that TAVI will be the dominant technology for the treatment of patients with valvular heart diseases. Overall, then, this study shows that new technology of transcatheter aortic valve implantation (TAVI) introduced in 2002 is growing in terms of scientific, inventive and innovative activity to revolutionize the management of aortic stenosis in cardiology worldwide.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
